LADU, SARA
 Distribuzione geografica
Continente #
EU - Europa 614
NA - Nord America 589
AS - Asia 341
SA - Sud America 1
Totale 1.545
Nazione #
US - Stati Uniti d'America 589
CN - Cina 202
UA - Ucraina 139
TR - Turchia 115
IE - Irlanda 107
GB - Regno Unito 81
SE - Svezia 80
FR - Francia 66
IT - Italia 53
DE - Germania 48
FI - Finlandia 30
IN - India 20
GR - Grecia 4
IL - Israele 4
AT - Austria 2
RU - Federazione Russa 2
AR - Argentina 1
DK - Danimarca 1
RO - Romania 1
Totale 1.545
Città #
Jacksonville 168
Chandler 137
Dublin 106
Southend 80
Beijing 58
Princeton 57
Nanjing 56
Izmir 43
Altamura 35
Cambridge 28
Boardman 23
Nanchang 22
Wilmington 21
Ashburn 17
Kunming 15
Shenyang 11
Tianjin 9
Dearborn 8
Hebei 6
Chieti 5
Jiaxing 5
Norwalk 5
Changchun 4
Hangzhou 4
Changsha 3
Lanzhou 3
Grevenbroich 2
Hefei 2
Helsinki 2
New York 2
Shanghai 2
Vienna 2
Andover 1
Ann Arbor 1
Apo 1
Berlin 1
Chicago 1
Düsseldorf 1
Fairfield 1
Haikou 1
Irvine 1
Kemerovo 1
Milan 1
Moreno 1
Napoli 1
Palermo 1
Saint Louis 1
San Benedetto del Tronto 1
Tel Aviv 1
Temecula 1
Vasto 1
Totale 960
Nome #
The SHP-1 expression is associated with cytokines and psychopathological status in unmedicated first episode schizophrenia patients 88
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis 70
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. 66
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. 63
Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. 60
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. 60
Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. 59
Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. 59
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. 58
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. 58
Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. 58
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. 57
Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. 57
Oncogenic and tumor suppressive roles of Polo-like kinases in human hepatocellular carcinoma (p NA). 56
Disregulation of E-cadherin in transgenic mouse models of liver cancer. 56
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. 56
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. 56
Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. 53
Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. 53
Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis. 52
Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. 52
Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. 52
The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. 51
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. 50
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value 45
Downregulation of PH domain leucine-rich repeat protein phosphatases (PHLPPs) identifies a subgroup of human hepatocellular and colorectal carcinomas with elevated levels of activated AKT and low apoptosis rate 42
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways 39
Yes-Associated Protein Upregulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. 35
Totale 1.561
Categoria #
all - tutte 5.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.754


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201948 0 0 0 0 0 0 0 0 0 0 0 48
2019/2020332 114 28 0 1 28 10 33 30 0 41 47 0
2020/2021119 28 0 28 0 1 30 0 1 4 25 0 2
2021/2022101 0 0 0 19 8 0 3 4 13 3 15 36
2022/2023422 30 52 26 43 47 96 24 36 56 1 3 8
2023/2024109 22 5 1 1 9 38 32 0 0 0 1 0
Totale 1.561